Bortezomib and PS-1145 both effectively reduce serum cytokine levels in mice with GVHD. Lethally irradiated (1000 cGy) B6 mice underwent transplantation with TCD B10.BR BM alone (□) or with B10.BR spleen cells adjusted to yield a dose of 2 × 106 T cells. Mice that received transplanted T cells were left untreated (▪) or were administered bortezomib (1 mg/kg, day 0) (▦) or PS-1145 (50 mg/kg, days 0-2) (▨). Mice in all groups were bled on day 7 after BMT and were analyzed for the specified cytokines. Data are cumulative results from 2 independent experiments with 5 to 7 mice per group. Data are presented as the mean ± SEM. IL-2: bortezomib or PS-1145 versus GVHD control, P < .005. TNF-α: bortezomib or PS-1145 versus GVHD control, P = .02. IL-10: bortezomib or PS-1145 versus GVHD control, P < .005.
